Sanofi/GSK Working With The US To Increase COVID-19 Vaccine Capacity
Executive Summary
The $2.1bn investment under the US’ Operation Warp Speed will fund development, scale-up of US manufacturing and the first 100 million doses.
You may also be interested in...
Divided House On Challenge Trials For COVID-19 Vaccines But Collaboration Goals Unite
High-profile experts including Anthony Fauci and Adrian Hill share views at the ICMR symposium on progressing safe COVID-19 vaccines backed by ethical trials executed with appropriate scientific rigor. Human challenge studies, "vaccine nationalism" and equitable access were among the key issues deliberated, while India committed to making its coronavirus vaccines and related capabilities available to the world.
Sanofi Forecasts Strong Flu Vaccine Growth, Accelerates COVID Plans
While Dupixent and oncology provide the backbone for future growth, Sanofi could seize an opportunity to expand its vaccines business greatly.
GSK Vaccine Sales Hit By COVID-19 But Initial Signs Of Recovery
GlaxoSmithKline sees initial signs of recovery from the coronavirus pandemic in terms of vaccination rates and highlights its growing research progress against COVID, RSV and meningitis, although a UK expert warns against over-optimism.